|43.73||+1.35||+3.19%||Vol 113.61K||1Y Perf -3.94%|
|Jun 27th, 2022 16:00 DELAYED|
|- -||- -%|
|Target Price||48.50||Analyst Rating||Moderate Buy 2.33|
|Potential %||10.91||Finscreener Ranking||★★ 46.23|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||★★★+ 53.76|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||★★★★ 57.99|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Price Range Ratio 52W %||15.78||Earnings Rating||Strong Sell|
|Market Cap||577.85M||Earnings Date||8th Aug 2022|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||8th Aug 2022|
|Estimated EPS Next Report||2.48|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||184.05K|
|Avg. Monthly Volume||150.75K|
|Avg. Quarterly Volume||135.38K|
Eagle Pharmaceuticals Inc. (NASDAQ: EGRX) stock closed at 43.73 per share at the end of the most recent trading day (a 3.19% change compared to the prior day closing price) with a volume of 113.61K shares and market capitalization of 577.85M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 108 people. Eagle Pharmaceuticals Inc. CEO is Scott L. Tarriff.
The one-year performance of Eagle Pharmaceuticals Inc. stock is -3.94%, while year-to-date (YTD) performance is -14.12%. EGRX stock has a five-year performance of -45.74%. Its 52-week range is between 41.01 and 58.25, which gives EGRX stock a 52-week price range ratio of 15.78%
Eagle Pharmaceuticals Inc. currently has a PE ratio of 15.20, a price-to-book (PB) ratio of 2.59, a price-to-sale (PS) ratio of 2.35, a price to cashflow ratio of 487.90, a PEG ratio of 2.32, a ROA of 12.68%, a ROC of 15.50% and a ROE of 18.09%. The company’s profit margin is 14.84%, its EBITDA margin is 23.20%, and its revenue ttm is $246.17 Million , which makes it $18.63 revenue per share.
Of the last four earnings reports from Eagle Pharmaceuticals Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $2.48 for the next earnings report. Eagle Pharmaceuticals Inc.’s next earnings report date is 08th Aug 2022.
The consensus rating of Wall Street analysts for Eagle Pharmaceuticals Inc. is Moderate Buy (2.33), with a target price of $48.5, which is +10.91% compared to the current price. The earnings rating for Eagle Pharmaceuticals Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Eagle Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Eagle Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 10.61, ATR14 : 1.92, CCI20 : -77.53, Chaikin Money Flow : 0.00, MACD : -1.00, Money Flow Index : 37.21, ROC : -10.59, RSI : 41.43, STOCH (14,3) : 18.05, STOCH RSI : 0.67, UO : 39.62, Williams %R : -81.95), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Eagle Pharmaceuticals Inc. in the last 12-months were:
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
This could take some time, please wait.